BioTime, Inc. (BTX) Reaches $2.97 After 5.00% Down Move, Centaur Capital Partners LP Has Cut By $632,500 Its Apple (AAPL) Position

June 19, 2017 - By marketbeat

Centaur Capital Partners Lp decreased Apple Inc (AAPL) stake by 21.15% reported in 2016Q4 SEC filing. Centaur Capital Partners Lp sold 5,500 shares as Apple Inc (AAPL)’s stock rose 12.78%. The Centaur Capital Partners Lp holds 20,500 shares with $2.37 million value, down from 26,000 last quarter. Apple Inc now has $749.68B valuation. The stock rose 2.50% or $3.56 reaching $145.83. About 15.27M shares traded. Apple Inc. (NASDAQ:AAPL) has risen 62.48% since June 19, 2016 and is uptrending. It has outperformed by 45.78% the S&P500.

The stock of BioTime, Inc. (NYSEMKT:BTX) is a huge mover today! About 238,536 shares traded. BioTime, Inc. (NYSEMKT:BTX) has risen 22.71% since June 19, 2016 and is uptrending. It has outperformed by 6.01% the S&P500.The move comes after 7 months negative chart setup for the $327.11M company. It was reported on Jun, 19 by Barchart.com. We have $2.82 PT which if reached, will make NYSEMKT:BTX worth $16.36 million less.

Since December 27, 2016, it had 0 buys, and 32 sales for $162.84 million activity. GORE ALBERT JR had sold 70,000 shares worth $8.98 million. Srouji Johny sold 13,207 shares worth $1.80M. LEVINSON ARTHUR D sold $5.39 million worth of Apple Inc. (NASDAQ:AAPL) on Tuesday, May 9. AHRENDTS ANGELA J had sold 75,000 shares worth $11.10M on Thursday, May 4. $735,898 worth of Apple Inc. (NASDAQ:AAPL) was sold by Maestri Luca on Friday, June 2. Another trade for 11,949 shares valued at $1.86 million was made by Riccio Daniel J. on Tuesday, May 16. 30,000 shares were sold by COOK TIMOTHY D, worth $3.60 million on Friday, January 20.

Investors sentiment decreased to 0.79 in Q4 2016. Its down 0.03, from 0.82 in 2016Q3. It is negative, as 90 investors sold AAPL shares while 975 reduced holdings. 123 funds opened positions while 723 raised stakes. 3.04 billion shares or 1.85% more from 2.98 billion shares in 2016Q3 were reported. Ntv Asset Mngmt Limited Company stated it has 1.59% of its portfolio in Apple Inc. (NASDAQ:AAPL). Moreover, Raymond James Finance Svcs Advsr has 1.72% invested in Apple Inc. (NASDAQ:AAPL) for 1.77M shares. Estabrook Cap Mngmt reported 0% of its portfolio in Apple Inc. (NASDAQ:AAPL). Osborne Ptnrs Cap Mgmt Ltd Llc stated it has 2.51% of its portfolio in Apple Inc. (NASDAQ:AAPL). York Capital Management Glob Advisors holds 0.12% or 38,543 shares. Assetmark invested 0.21% of its portfolio in Apple Inc. (NASDAQ:AAPL). Shoker Counsel Inc holds 0.5% of its portfolio in Apple Inc. (NASDAQ:AAPL) for 5,179 shares. Sageworth Trust has invested 0.02% of its portfolio in Apple Inc. (NASDAQ:AAPL). Inverness Counsel Llc has 1.55% invested in Apple Inc. (NASDAQ:AAPL) for 159,584 shares. Schmidt P J Inv Mgmt stated it has 60,365 shares. Daiwa Sb Invests Ltd invested in 97,510 shares. King Luther Capital Corp reported 2.26% in Apple Inc. (NASDAQ:AAPL). Novare Mgmt Limited Liability Company stated it has 2.27% in Apple Inc. (NASDAQ:AAPL). Cheviot Value Lc reported 38,257 shares stake. Holt Cap Advisors Limited Dba Holt Cap Ptnrs Limited Partnership has invested 1.4% of its portfolio in Apple Inc. (NASDAQ:AAPL).

Analysts await Apple Inc. (NASDAQ:AAPL) to report earnings on July, 25. They expect $1.57 earnings per share, up 10.56% or $0.15 from last year’s $1.42 per share. AAPL’s profit will be $8.07 billion for 23.22 P/E if the $1.57 EPS becomes a reality. After $2.10 actual earnings per share reported by Apple Inc. for the previous quarter, Wall Street now forecasts -25.24% negative EPS growth.

Among 45 analysts covering Apple Inc. (NASDAQ:AAPL), 35 have Buy rating, 1 Sell and 9 Hold. Therefore 78% are positive. Apple Inc. had 214 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Apple Inc. (NASDAQ:AAPL) earned “Buy” rating by Macquarie Research on Wednesday, October 28. Credit Suisse maintained the shares of AAPL in report on Monday, April 4 with “Outperform” rating. Morgan Stanley maintained the shares of AAPL in report on Tuesday, February 21 with “Overweight” rating. The rating was maintained by UBS on Tuesday, September 20 with “Buy”. The stock of Apple Inc. (NASDAQ:AAPL) earned “Buy” rating by UBS on Wednesday, October 12. Nomura maintained it with “Buy” rating and $120 target in Wednesday, April 27 report. The firm has “Overweight” rating given on Wednesday, April 27 by Piper Jaffray. The firm has “Hold” rating given on Wednesday, October 28 by Mizuho. The firm has “Buy” rating given on Wednesday, October 28 by Stifel Nicolaus. The stock of Apple Inc. (NASDAQ:AAPL) has “Market Perform” rating given on Tuesday, August 25 by Cowen & Co.

BioTime, Inc. is a clinical-stage biotechnology firm focused on developing and commercializing products addressing degenerative diseases. The company has market cap of $327.11 million. The Company’s clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. It has a 3.05 P/E ratio. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: